Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence
Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, Lieberman JA
Published in Neuroscience, Vol. 191, pp. 78-90
Methodology
Systematic review of clinical trials of pregnenolone and allopregnanolone in schizophrenia, mood and anxiety disorders with neurosteroid measurement.
Key Findings
Pregnenolone administration raised downstream neurosteroid levels and improved negative symptoms and cognition in some but not all trials.
Conclusions
Pregnenolone supplementation reliably alters neurosteroid levels with inconsistent clinical benefit.
Limitations
Small trials; heterogeneous doses and populations.
Outcomes Measured
Pregnenolone administration raised downstream neurosteroid levels and improved negative symptoms and cognition in some but not all trials
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.